Monday, July 30, 2012
Endocyte, an Indianapolis, Ind.-based biopharmaceutical company focused on cancer and inflammatory diseases, has appointed David Meek to the newly created position of chief commercial officer. He will be responsible for the development of Endocyte’s commercial team and overall commercial strategy and execution.
Meek brings more than 20 years of pharmaceutical industry experience, including general management in North America and Europe, and numerous successful launches for oncology and specialty products. He comes to Endocyte after more than seven years at Novartis Pharma, where he was most recently the head of Northern and Central Europe oncology and launched key new oncology products and indications for Novartis. Previously, Meek served as president and CEO of Novartis Pharmaceuticals Canada, where he oversaw the launch of Lucentis and other specialty products. Prior to his roles at Novartis, Meek served at Johnson & Johnson for 15 years, where he held a variety of senior sales and marketing roles across multiple therapeutic areas, including oncology.